title: Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients.
abstract: OBJECTIVE
  To evaluate the treatment options for nephrotoxicity due to cisplatin combination chemotherapy.
  
  
  METHODS
  We retrospectively reviewed patients who had received cisplatin combination chemotherapy for gastric cancer between January 2002 and December 2008. We investigated patients who had shown acute renal failure (ARF), and examined their clinical characteristics, laboratory data, use of preventive measures, treatment cycles, the amount of cisplatin administered, recovery period, subsequent treatments, and renal status between the recovered and unrecovered groups.
  
  
  RESULTS
  Forty-one of the 552 patients had serum creatinine (SCR) levels greater than 1.5 mg/dL. We found that pre-ARF SCR, ARF SCR, and ARF glomerular filtration rates were significantly associated with renal status post-ARF between the two groups (P = 0.008, 0.026, 0.026, respectively). On the receiver operating characteristic curve of these values, a 1.75 mg/dL ARF SCR value had 87.5% sensitivity and 84.8% specificity (P = 0.011).
  
  
  CONCLUSIONS
  Cessation or reduction of chemotherapy should be considered for patients who have an elevation of SCR levels during cisplatin combination chemotherapy.
authors.affiliation: Department of Surgery, Kosin University College of Medicine, 602-703 Busan, South Korea.
authors.forename: Hyung Hwan
authors.initials: HH
authors.lastname: Moon
authors.forename: Kyung Won
authors.initials: KW
authors.lastname: Seo
authors.forename: Ki Young
authors.initials: KY
authors.lastname: Yoon
authors.forename: Yeon Myung
authors.initials: YM
authors.lastname: Shin
authors.forename: Kyung Hyun
authors.initials: KH
authors.lastname: Choi
authors.forename: Sang Ho
authors.initials: SH
authors.lastname: Lee
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced / Q000503:physiopathology; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin